AIDS is becoming a chronic disease. According to data, size of the global HIV drug market approached USD 23.5 billion in 2017. Gilead dominates the global HIV drug market: it occupied more than half of the relevant global market share according to 2017 data, and its triple/quadruple regimen of 2NRTI+INSTI/NNRTI based on TAF is becoming the mainstream regimen of the HIV drug market. Here, I analyze and organize the 10-year market data of main HIV drugs on the global market, and give an overview of the global HIV drug market from the perspective of company, product, and drug combination regimen.
I. Global market share reached USD 23.3 billion, with Gilead dominating the HIV drug market
Gilead, GSK, BMS, and MSD are the leading companies on global HIV drug market, especially, Gilead: it alone occupied 51% share of the global HIV drug market (the statistical data below include its HBV drug sales). With the declining of its HCV DAA business, Gilead’s HIV drug business continues to rapidly grow, especially, the success of the new-generation HIV drugs based on TAF have brought a new growth point to Gilead, and led to the most brilliant financial report data of Gilead (see Gilead Released 2017 Financial Report: HCV Drug Business Continued to Slump while the New-generation HIV Drug Products Surged by 184% for the details).
|
2008-2017年全球艾滋病市场主要公司销售额 （百万，美金） |
Sales of Major Companies on the Global HIV Drug Market from 2008 to 2017 (USD 1 million) |
II. The quadruple regimen Genvoya fast growing into a star of today
The success of the cocktail therapy has brought breakthroughs to AIDS control. The STRs (single-tablet regimens) have significantly prolonged patients’ lifetime, and their market share is rapidly expanding. STRs accounted for 72% share of global HIV drug market by 2017, and this figure will continue to increase.
|
单方 VS STR市场份额% 单方 |
Market Shares of Single Drugs vs STRs Single drugs |
From the perspective of single product: the quadruple regimen Genvoya becoming the star of today, with 2017 sales reaching USD 3.7 billion
|
2008-2017年全球艾滋病市场主要产品销售额 （百万，美金） |
Sales of Major Products on the Global HIV Drug Market from 2008 to 2017 (USD 1 million) |
From the perspective of category, HIV drugs are mainly divided into nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), integrase strand transfer inhibitors (INSTIs), and protease inhibitors (PIs), etc., and the cocktail therapies that combine 2NRTI and other antivirals are currently the most successful AIDS control regimen.
Genvoya is a new quadruple regimen, with 2NRTI+INSTI+PK enhancer. Its sales have been adva...
(All Rights Reserved)